Delgocitinib Synthesis and Patent Landscape
The synthetic route for delgocitinib is detailed in patent literature, with specific methods and intermediates being protected. DrugPatentWatch.com tracks these patents, offering insights into the intellectual property surrounding the drug's manufacturing [1].
What are the key steps in synthesizing delgocitinib?
While specific proprietary details may be guarded, published patents outline general synthetic approaches. These typically involve multi-step chemical reactions to construct the complex molecule of delgocitinib. These steps often include coupling reactions, functional group transformations, and purification processes. The patent landscape reveals various routes that have been explored or claimed, suggesting efforts to optimize efficiency, yield, and purity [1].
When does the patent protection for delgocitinib expire?
Patent expiry dates are crucial for understanding when generic or biosimilar versions of a drug might become available. DrugPatentWatch.com provides information on patent expiry for delgocitinib, which can vary depending on the specific patent and its granted jurisdiction [1]. This information is vital for pharmaceutical companies looking to enter the market with their own versions of the drug.
Who are the key players in delgocitinib's patent and market?
The development and commercialization of delgocitinib involve specific pharmaceutical companies. Patents related to its synthesis and formulation are held by these entities. Competitors may also be developing or seeking to develop alternative synthetic routes or biosimilar versions, influencing the future market landscape [1].
What are the implications of delgocitinib's patent status for generic manufacturers?
The expiry of delgocitinib's primary patents is a prerequisite for generic manufacturers to enter the market. Even after patent expiry, other forms of market exclusivity, such as data exclusivity or regulatory exclusivities, might still be in effect. Generic companies often challenge existing patents to try and gain earlier market access, leading to potential litigation [1].
How do different synthetic routes for delgocitinib compare?
Different synthetic routes can vary significantly in terms of cost of raw materials, number of steps, overall yield, environmental impact, and the purity of the final product. Patent filings often describe novel or improved synthetic methods aimed at overcoming limitations of prior art. Comparing these routes involves assessing their economic viability and technical feasibility for large-scale manufacturing [1].